Sysmex America announced it will add the the CellaVision DC-1 to its portfolio of CellaVision products for low-volume hematology labs, according to a press release from the company.
The product, which received the Food and Drug Administration’s 510(k) clearance on October 16, 2020, is available for sale in the United States and Canada.
The CellaVision DC-1 automates and simplifies the process of performing blood cell differentials in low volume labs, according to a press release from Sysmex America. The CellaVision DC-1 eliminates the majority of manual steps traditionally done by lab technicians performing blood cell differentials for maximum speed and productivity, according to the release.
